dyslipidaemia

in review 8 min read Updated 2026-10-22
dyslipidaemia

LDL is causal: each 1 mmol/L reduction → 20–22% relative risk reduction, so absolute benefit = baseline risk × how much LDL can fall. Statin-indicated conditions (ASCVD, AAA >3 cm, most diabetes, CKD not on dialysis, LDL ≥5.0) → statin without a risk score. Everyone else → FRS (or CLEM) every 5 years from 40–75: high (≥20%) treat; intermediate (10–19.9%) treat if LDL ≥3.5 or risk modifiers; low (<10%) lifestyle. Once on a maximally tolerated statin, CCS uses intensification thresholds, not targets: ASCVD LDL ≥1.8 (non-HDL ≥2.4, apoB ≥0.7) → ezetimibe and/or PCSK9 inhibitor; PCSK9 inhibitor first if far above threshold or a high-benefit group. TG >1.5 → use non-HDL or apoB, not LDL. Lp(a) once in a lifetime. TG 1.5–5.6 on statin with ASCVD (or diabetes + risk factor) → icosapent ethyl; OTC omega-3 does nothing.


who gets a statin

statin-indicated conditions — no risk score needed

conditioncriterion
ASCVDMI/[[acute coronary syndromes
[[aortic aneurysmAAA]]
diabetesage ≥40, or ≥30 with ≥15 y duration, or microvascular disease
[[chronic kidney diseaseCKD]]
LDL ≥5.0 mmol/Lor apoB ≥1.45 g/L or non-HDL ≥5.8 — presumed genetic (FH)

primary prevention by FRS

Calculator: CCS Framingham Risk Score (also in the iCCS app).

FRS (10-year)statin if
high ≥20%all
intermediate 10–19.9%LDL ≥3.5 (non-HDL ≥4.2, apoB ≥1.05); or men ≥50 / women ≥60 with 1 extra risk factor (low HDL, IFG, high waist, smoking, HTN — HOPE-3 (2016)); or risk modifiers: hsCRP ≥2.0 mg/L, CAC >0, family history of premature CAD, Lp(a) ≥100 nmol/L
low 5–9.9%LDL ≥3.5 (non-HDL ≥4.2, apoB ≥1.05), especially with risk modifiers — treat as intermediate
low <10% otherwiselifestyle only
  • Premature family history (first-degree male ≤55, female ≤65) roughly doubles FRS in ages 30–59 without diabetes
  • benefit likely continues >75 in primary prevention
  • Lifestyle for all: Mediterranean-pattern diet, ≥150 min/week moderate–vigorous aerobic activity, smoking cessation
  • Ontario: apoB and Lp(a) are not insured

CAC — when the decision is genuinely uncertain

  • use: asymptomatic, ≥40 y, intermediate FRS, decision uncertain; not if high risk or already on a statin
  • CAC 0 → reasonable to withhold statin except smokers, diabetes, FH/high Lp(a), strong family history (calcium appears late → CAC 0 reassures least <50 y and in women)
  • CAC 1–99 → shared decision; CAC >100 → statin regardless of FRS
  • don’t repeat CAC to monitor statin effect (statins can raise CAC)

thresholds for adding therapy

All on a maximally tolerated statin first — high-intensity (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) for all ASCVD (strong). Low or very low LDL on treatment → no down-titration.

groupadd therapy ifadd
ASCVDLDL ≥1.8 / non-HDL ≥2.4 / apoB ≥0.7algorithm below
diabetes, CKD (statin-indicated, no ASCVD)LDL ≥2.0 / non-HDL ≥2.6 / apoB ≥0.8ezetimibe first (bile acid sequestrant alternative)
LDL ≥5.0 / FH without ASCVDLDL ≥2.5 or <50% reduction / non-HDL ≥3.2 / apoB ≥0.85ezetimibe or PCSK9 inhibitor (strong for PCSK9i in heterozygous FH)
primary prevention, FRS-basedLDL ≥2.0 / non-HDL ≥2.6 / apoB ≥0.8, or <50% reductiondiscuss ezetimibe
flowchart TD
    A[ASCVD on maximally tolerated statin] --> B{LDL ≥1.8 or non-HDL ≥2.4<br/>or apoB ≥0.7?}
    B -- No --> C[Continue<br/>add-on may still be considered if very high risk]
    B -- Yes --> D{LDL >2.2, non-HDL >2.9, apoB >0.8<br/>or high-benefit group?}
    D -- No: LDL 1.8–2.2 --> E[Ezetimibe ± PCSK9 inhibitor]
    D -- Yes --> F[PCSK9 inhibitor ± ezetimibe]
    E -. still above threshold .-> F
    A --> G{Fasting TG 1.5–5.6?}
    G -- Yes --> H[Icosapent ethyl 2 g BID]

High-benefit groups for PCSK9 inhibitors (strong) — the subgroups with the largest absolute benefit in FOURIER/ODYSSEY:

  • ACS within the past 52 weeks
  • ASCVD plus any of: diabetes or metabolic syndrome, polyvascular disease (≥2 beds), symptomatic PAD, recurrent MI, MI within 2 years, prior CABG, LDL ≥2.6 or heterozygous FH, Lp(a) ≥120 nmol/L

Ezetimibe lowers LDL ~20% on top of a statin → can’t close a large gap; LDL >2.2 favours a PCSK9 inhibitor. Drug plans may still require an ezetimibe trial first.


non-statin agents

agentLDL ↓outcome evidencenotes
ezetimibe 10 mg~20% (with statin)IMPROVE-IT (2015): ACS, HR 0.94, NNT 50 over 7 ymodest, slow-accruing benefit
PCSK9 inhibitor — evolocumab 140 mg SC q2wk / 420 mg monthly; alirocumab 75–150 mg SC q2wk50–70%FOURIER (2017): HR 0.85, NNT 67 over 2.2 y; ODYSSEY OUTCOMES (2018): ACS 1–12 mo, HR 0.85no mortality benefit shown (short follow-up); injection-site reactions; also ↓ Lp(a) ~15–30%
icosapent ethyl 2 g BID— (TG ↓ ~18%)REDUCE-IT (2019): HR 0.75, NNT 21 over 4.9 y, ↓ CV death↑ AF and peripheral oedema; purified EPA only
bempedoic acid 180 mg daily~20% (16–22%)CLEAR Outcomes (2023): statin-intolerant, MACE-4 HR 0.87gout, cholelithiasis, tendon rupture; raises simvastatin levels (≤20 mg)
micronised fenofibrate—no new CCS 2021 recommendationTG ≥10 mmol/L or TG-related pancreatitis
bile acid sequestrantmodestinconclusivealternative to ezetimibe
  • statin intolerance: rechallenge at a lower dose or different statin first; bempedoic acid is the only non-statin with outcome data in statin intolerance (CLEAR Outcomes); ezetimibe or PCSK9 inhibitor lower LDL but lack replacement-outcome data
  • inclisiran (twice-yearly siRNA): ~50% LDL lowering, outcome trials pending → second-line to PCSK9 antibodies

triglycerides

  • TG >1.5 mmol/L → LDL-C underestimates atherogenic particle number (TG-rich, small dense LDL; remnants) → screen and follow with non-HDL or apoB (strong)
  • Non-fasting lipids for screening and follow-up, except known TG >4.5 → fasting sample
  • TG 1.5–5.6 on maximally tolerated statin + ASCVD, or diabetes + ≥1 risk factor → icosapent ethyl (strong); preferentially ≥45 y (or ≥50 with a risk factor)
  • Mixed EPA/DHA at the same dose failed — STRENGTH (2020) → REDUCE-IT result does not extend to other omega-3 products
  • OTC omega-3 / fish oil → not for CV risk reduction (strong)
  • severe hypertriglyceridaemia (≥5.7 mmol/L, especially ≥10) or TG-related pancreatitis → fenofibrate to prevent pancreatitis

special populations

  • After pregnancy complications (hypertensive disorders, gestational diabetes, preterm birth, stillbirth, low birthweight, abruption) → lipid panel late postpartum (strong); preeclampsia ≈ 2× premature ASCVD at 10–15 years. Use CV age / lifetime risk, not 10-year FRS, for statin decisions
  • Reproductive age on a statin: prefer hydrophilic agents (rosuvastatin, pravastatin); effective contraception; stop before planned pregnancy or at a positive test, resume after breastfeeding
  • Heterozygous FH: PCSK9 inhibitor if above the FH threshold despite statin ± ezetimibe — covered by most provincial plans (unlike ASCVD)
  • Dialysis: not a statin-indicated condition — no initiation for CKD alone
  • Elevated Lp(a): earlier, more intensive risk-factor management; in ASCVD favours PCSK9 inhibitor → lipoprotein(a)

monitoring

  • TG <1.5 → follow LDL, non-HDL or apoB; TG ≥1.5 → non-HDL or apoB
  • lipids 4–12 weeks after starting or changing therapy, then every 6–12 months
  • Reassess FRS every 5 years (40–75) or when risk status changes

Prepared 2026-10-22. Not yet verified — check every number against the sources.

Key references

+5 more sources

Suggest a correction dyslipidaemia